This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Roche Molecular Systems Inc.
Roche Molecular Systems Inc., a subsidiary of the global healthcare leader Roche Holding AG, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1995, the company has established itself as a key player in the molecular diagnostics industry, focusing on innovative solutions for disease detection and management. Roche Molecular Systems is renowned for its advanced diagnostic technologies, including PCR (polymerase chain reaction) and next-generation sequencing, which enable precise and timely results. Their commitment to research and development has led to significant milestones, including the launch of groundbreaking tests for infectious diseases and oncology. With a strong market position, Roche Molecular Systems continues to set industry standards, recognised for its contributions to personalised medicine and patient care. The company’s unique offerings and dedication to innovation solidify its reputation as a leader in molecular diagnostics.
DitchCarbon Score
How does Roche Molecular Systems Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Roche Molecular Systems Inc.'s score of 83 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Roche Molecular Systems Inc., headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Roche Holding AG, which may influence its climate commitments and reporting practices. While Roche Molecular Systems Inc. has not set specific reduction targets or initiatives at its level, it inherits climate commitments and performance data from Roche Holding AG. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which are aimed at reducing greenhouse gas emissions across its operations. As a part of Roche Holding AG's broader sustainability strategy, the company is committed to addressing climate change and reducing its carbon footprint, although specific targets and achievements for Roche Molecular Systems Inc. have not been detailed. The absence of direct emissions data suggests that the company may still be in the process of establishing its own specific climate action framework, aligned with the overarching goals of its parent organisation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 249,350,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 114,452,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 6,402,719,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Roche Molecular Systems Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
